Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy

• Egile Nagusiak: Teerachat Punnachet (Egilea), Tim R. Cressey (Egilea), Porntipa Apiwatnakorn (Egilea), Atisa Koonarat (Egilea), Lalita Norasetthada (Egilea), Adisak Tantiworawit (Egilea), Ekarat Rattarittamrong (Egilea), Thanawat Rattanathammethee (Egilea), Sasinee Hantrakool (Egilea), Pokpong Piriyakhuntorn (Egilea), Nonthakorn Hantrakun (Egilea), Piangrawee Niprapan (Egilea), Chatree Chai-Adisaksopha (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2024-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

<b>Background/Objectives</b>: Rivaroxaban and dabigatran are commonly used for thromboembolic disease management in active cancer patients. However, limited research explores the impact of concurrent chemotherapy on the pharmacodynamics of direct oral anticoagulants (DOAC). The aim of ou...